Now showing items 1-2 of 2

  • Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. 

    Rule, S; Jurczak, W; Jerkeman, M; Rusconi, C; Trneny, M; Offner, F; Caballero, D; Joao, C; Witzens-Harig, M; Hess, G; Bence-Bruckler, I; Cho, S-G; Thieblemont, C; Zhou, W; Henninger, T; Goldberg, J; Vermeulen, J; Dreyling, M (2018-02-02)
  • International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). 

    Younes, A; Hilden, P; Coiffier, B; Hagenbeek, A; Salles, G; Wilson, W; Seymour, JF; Kelly, K; Gribben, J; Pfreunschuh, M; Morschhauser, F; Schoder, H; Zelenetz, AD; Rademaker, J; Advani, R; Valente, N; Fortpied, C; Witzig, TE; Sehn, LH; Engert, A; Fisher, RI; Zinzani, P-L; Federico, M; Hutchings, M; Bollard, C; Trneny, M; Elsayed, YA; Tobinai, K; Abramson, JS; Fowler, N; Goy, A; Smith, M; Ansell, S; Kuruvilla, J; Dreyling, M; Thieblemont, C; Little, RF; Aurer, I; Van Oers, MHJ; Takeshita, K; Gopal, A; Rule, S; de Vos, S; Kloos, I; Kaminski, MS; Meignan, M; Schwartz, LH; Leonard, JP; Schuster, SJ; Seshan, VE (England, 2017-07-01)
    In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV